(VIANEWS) – Shares of ImmunoGen (NASDAQ: IMGN) jumped by a staggering 34.3% in 21 sessions from $13.73 at 2023-05-18, to $18.44 at 11:43 EST on Monday, following the last session’s downward trend. NASDAQ is falling 0.68% to $13,689.57, following the last session’s downward trend.
ImmunoGen’s last close was $18.44, 4.16% under its 52-week high of $19.24.
About ImmunoGen
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.93.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -111.95%.
Yearly Top and Bottom Value
ImmunoGen’s stock is valued at $18.44 at 11:43 EST, under its 52-week high of $19.24 and way above its 52-week low of $3.61.
Sales Growth
ImmunoGen’s sales growth is 214.7% for the ongoing quarter and 306.2% for the next.
Volume
Today’s last reported volume for ImmunoGen is 32053112 which is 320.6% above its average volume of 7620660.
More news about ImmunoGen (IMGN).
